Preventing cancer by targeting abnormally expressed self-antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas

Annals of the New York Academy of Sciences

Volumn 1284, Issue 1, 2013, Pages 52-56

  Beatty, Pamela L ^a   Finn, Olivera J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer vaccines; Immunosurveillance; MUC1; Tumor antigens; Tumor immunology

Indexed keywords

ANTIGEN; CANCER VACCINE; DISEASE ASSOCIATED ANTIGEN; MUC1 PEPTIDE VACCINE; MUCIN 1; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ARTICLE; AUTOIMMUNITY; CANCER PREVENTION; COLON ADENOMA; COLON CANCER; EPITHELIUM ADENOCARCINOMA; HUMAN; IMMUNOBIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR IMMUNITY;

EID: 84877332485     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12108     Document Type: Article

References (27)

1. Thun, M.J. et al. 2010. The global burden of cancer: priorities for prevention. Carcinogenesis 31: 100-110.
2. Finn, O.J. 2008. Cancer immunology. N. Engl. J. Med. 358: 2704-2715.
3. Schreiber, R.D., L.J. Old & M.J. Smyth 2011. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331: 1565-1570.
4. Beatty, P., S. Ranganathan & O.J. Finn 2012. Prevention of colitis-associated colon cancer using a vaccine to target abnormal expression of the MUC1 tumor antigen. Oncoimmunology 1: 263-270.
5. Beatty, P.L. et al. 2010. Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer. Cancer Prev. Res. 3: 438-446.
6. Vlad, A.M. et al. 2004. MUC1 immunobiology: from discovery to clinical applications. Adv. Immunol. 82: 249-293.
7. Barnd, D.L. et al. 1989. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc. Natl. Acad. Sci. USA 86: 7159-7163.
8. Jerome, K.R. et al. 1991. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. 51: 2908-2916.
9. Ioannides, C.G. et al. 1993. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J. Immunol. 151: 3693-3703.
10. Vlad, A.M. et al. 2002. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J. Exp. Med. 196: 1435-1446.
11. von Mensdorff-Pouilly, S. et al. 2000. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J. Clin. Oncol. 18: 574-583.
12. Hamanaka, Y. et al. 2003. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int. J. Cancer. 103: 97-100.
13. Pinheiro, S.P. et al. Anti-MUC1 antibodies and ovarian cancer risk: prospective data from the Nurses' Health Studies. Cancer Epidemiol. Biomarkers Prev. 19: 1595-1601.
14. Cramer, D.W. et al. 2005. Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 14: 1125-1131.
15. -/- mice accelerates inflammatory bowel disease and progression to colon cancer. J. Immunol. 179: 735-739.
16. Vlad, A.M., I. Diaconu & K.R. Gantt 2006. MUC1 in endometriosis and ovarian cancer. Immunol. Res. 36: 229-236.
17. Kadayakkara, D.K. et al. 2010. Inflammation driven by overexpression of the hypoglycosylated abnormal mucin 1 (MUC1) links inflammatory bowel disease and pancreatitis. Pancreas 39: 510-515.
18. Wiseman, E.F. & Y.S. Ang 2011. Risk factors for neoplastic progression in Barrett's esophagus. World J. Gastroenterol. 17: 3672-3683.
19. Mariette, C. et al. 2008. Activation of MUC1 mucin expression by bile acids in human esophageal adenocarcinomatous cells and tissues is mediated by the phosphatidylinositol 3-kinase. Surgery 143: 58-71.
20. Yonezawa, S. et al. 2008. Precursor lesions of pancreatic cancer. Gut Liver 2: 137-154.
21. Finn, O.J. et al. 2011. Importance of MUC1 and spontaneous mouse tumor models for understanding the immunobiology of human adenocarcinomas. Immunol. Res. 50: 261-268.
22. Ajioka, Y., H. Watanabe & J.R. Jass 1997. MUC1 and MUC2 mucins in flat and polypoid colorectal adenomas. J. Clin. Pathol. 50: 417-421.
23. Ho, S.B. et al. 1996. Altered mucin core peptide immunoreactivity in the colon polyp-carcinoma sequence. Oncol. Res. 8: 53-61.
24. Zotter, S. et al. 1987. Immunohistochemical localization of the epithelial marker MAM-6 in invasive malignancies and highly dysplastic adenomas of the large intestine. Lab. Invest. 57: 193-199.
25. Kimura, T. et al. 2013. MUC1 vaccine for individuals with advanced adenoma of the colon: a Cancer Immunoprevention Feasibility Study. Cancer Prev. Res. 6: 18-26.
26. + T lymphocytes. Science 319: 215-220.
27. Vella, L.A. et al. 2009. Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer. Proc. Natl. Acad. Sci. USA 106: 14010-14015.